The Avastin Dilemma: Two Personalities and Two Points of View on Cost Effectiveness
This article was originally published in RPM Report
Executive Summary
Two of the key figures in the 2009 health reform debate, Zeke Emanuel and Billy Tauzin, each use Genentech's Avastin to demonstrate the importance of doing cost effectiveness right. But they look at the same drug from very different points of view. Their perspectives provide a good guide to what is at stake in the design of federal approach to comparative effectiveness research.
You may also be interested in...
The Zaltrap Price Debate: Less Than Meets The Eye
Sanofi is responding to critics of the Zaltrap price with a 50% discount. Is this a “watershed” moment for cancer drug prices? Probably not. The real test will come when payors resist a price on a drug with a proven therapeutic advantage – and when the drug really matters to the sponsor.
Ending “Buy-And-Bill” in Oncology: The Question is How, Not If
The public policy debate over affordability of cancer care is approaching consensus on the need to end the “buy-and-bill” model for chemotherapy. How, and how fast, are the key remaining questions. For biopharma manufacturers, there are good reasons to embrace the change.
Early Notification Legislation: What The Bills Say
Both houses have introduced legislation to require manufacturers to notify FDA in advance of planned interruptions or as soon as possible when facing a shortage. Here’s a look at the details.